Stocks to Buy: Motilal Oswal 'bull case' sees 70% upside for new listing already doubled from IPO price
In the base case, Motilal Oswal has assigned a 45-times 12-month forward price-to-earnings multiple to Molbio Diagnostics, a 20% premium to its sector multiple of 36 times, citing the company's differentiated research-and-development-led business model and earnings growth potential.
In the base case, Motilal Oswal has assigned a 45-times 12-month forward price-to-earnings multiple to Molbio Diagnostics, a 20% premium to its sector multiple of 36 times, citing the company's differentiated research-and-development-led business model and earnings growth potential.
What's Your Reaction?
